Clinical trial
A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent…
NCT00090545 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00090545 |
|---|---|
| Title | A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer |
| Official title | A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | BAY 43-9006 |
| Enrollment | 46 |
| Start date | Sep 1, 2004 |
| Primary completion | Sep 1, 2007 |
| Completion | Apr 1, 2009 |
| First posted | Aug 27, 2004 |
| Last update posted | Jun 14, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: